Zdrowie i gospodarka · 19/12/2011
FDA Clears Bretylium Tosylate Injection for Potential Approval
The FDA has determined that Bretylium Tosylate injection, 50 mg/mL, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs).
Source: Federal Register — Health and Human ServicesOpen original release →